FICHIT

Je m'inscris

EFFIMUNE

0/5 (0 note(s))
Note donnée : aucune
Paris
0
Biotech company dedicated to the discovery and development of drugs which regulate the immune system in autoimmune disease, transplantation and cancer immunotherapy.
The 1st product-candidate, called FR104, resulting from company’s research platform is currently in clinical Phase I trial in transplantation and rheumatoid arthritis in the frame of a licensing agreement with Janssen Biotech Inc. FR104 is a monovalent antibody fragment antagonist of the T-cell costimulator CD28. FR104 tips the balance of the immune response towards a pro-tolerogenic response and therefore provides a long-lasting pharmacological effect that has been demonstrated in preclinical models of organ and bone marrow transplantation, multiple sclerosis and rheumatoid arthritis.
VANHOVE Bernard
www.effimune.com
Private Equity

Fiche créée le 10/04/2016 par Guillaume   vue 4 fois.